In the current meta-analysis, we intended to comprehensively review the evidence on the association between income and hepatitis B seroprevalence. Based on the findings, there was a significant association between pooled effect sizes of income and HBsAg seroprevalence. The results also revealed a borderline significant association between income and hepatitis B seroprevalence (positive for 1 or more seromarkers). However, the association between income and Anti-HBs seroprevalence was not statistically significant. The same was true about the association between income and Anti-HBc seroprevalence.
HBsAg is an antigen on the surface of HBV that indicates current hepatitis B infection. Currently, vaccination is the most effective mean to prevent HBV infection, which can decrease the HBsAg seroprevalence (
29). According to the findings of the present study, income inequality is associated with an increased risk of HBsAg seroprevalence. This might because income is one of the determinants of willingness to pay for the hepatitis B vaccine, and the lower the income, the lower would be the willingness to pay (
30). Moreover, compared to those from higher income groups, those with lower income usually have lower levels of awareness about hepatitis B (
31) and often have worse living habits (i.e., sharing toothbrushes, razor or nail clippers) (
32), which both increase the risk of HBV infection.
As mentioned above, income contributes to the willingness to pay for the HBV vaccine (
33-
35). Based on this guess, income inequality should be associated with Anti-HBs. However, no statistically significant association was found between income and Anti-HBs seroprevalence. However, this can be due to the inadequacy of literature and the low number of studies that were investigated in the present study.
To the best of our knowledge, this is the first meta-analysis assessing income effects on hepatitis B seroprevalence. However, there are limitations to our study, which should be noted. First, pooled estimates were affected by high heterogeneity. Although we performed a subgroup analysis separated by gender, region, marker, and quality score, we couldn’t identify the source of heterogeneity. Second, we couldn't calculate the difference between subgroups (i.e., the different distribution of seroprevalence of different markers among various income groups), because in one study the sample size of seropositive people was not clear (
24). Third, all included studies were case-control studies, which are prone to recall bias. Fourth, the results of sensitivity analysis for hepatitis B seroprevalence (positive for 1 or more seromarkers) and Anti-HBs were both inconsistent. In other words, the associations between income and hepatitis B seroprevalence (positive for 1 or more seromarkers) and anti-HBs were not yet clear.
By taking these limitations into account, future research should pay more attention to the association between anti-HBS and income, so as to provide more material for meta-analysis. Additionally, future studies should aim to unpack the mechanism underlying the association between income and hepatitis B seroprevalence, in particular, to identify the potential factors that influence this association.
In conclusion, this study demonstrated a positive association between low income and risk of HBsAg seroprevalence. Hence, public health programs, particularly those related to hepatitis B prevention, should pay special attention to income inequality, in addition to emphasizing low-income populations.